Skoulidis and colleagues, in a retrospective analysis including 174 patients with KRAS mutant lung adenocarcinoma treated with nivolumab, showed significantly lower ORR among patients with STK11 alterations than among those with TP53 alterations (7.4% vs. 35.7%). Here, KRAS is linked to lung adenocarcinoma.